MedPath

sing advanced MRI sequence to distinguish between cancer and radiation induced damage in treated brain tumors like Glioma

Not Applicable
Conditions
Health Condition 1: C71- Malignant neoplasm of brain
Registration Number
CTRI/2024/03/064109
Lead Sponsor
Dr ARPITA SAH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients with histologically proven higher grade gliomas who underwent treatment (chemotherapy, radiotherapy or both) and having suspicion for tumor recurrence or radiation necrosis.

Exclusion Criteria

1.Patients with non-glial tumors on histology.

2.Patients who do not have tissue diagnosis or are lost on imaging follow up.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To assess the utility of Arterial Spin Labeling (ASL) in brain tumor protocol for distinguishing tumor recurrence from radiation necrosis in treated cases of grade 3 and 4 gliomas.Timepoint: Project time is 3 years.
Secondary Outcome Measures
NameTimeMethod
1.To compare findings of perfusion i.e.Arterial Spin Labeling (ASL) and Dynamic Susceptibility Contrast (DSC) MRI. <br/ ><br>2.Quantitative analysis of ASL, DSC findings. <br/ ><br>3.Qualitative analysis of ASL and DSC perfusion maps. <br/ ><br>4.To assess anyaltered signal by other MR sequences – T1W, T2W, T1 FLAIR, Post contrast T1, Post contrast T2 FLAIR, Diffusion weighted imaging, Spectroscopy. <br/ ><br>5.Comparison of MRI results with amino acids.Timepoint: Project time is 3 years.
© Copyright 2025. All Rights Reserved by MedPath